Abstract
Ninety percent of all cancer deaths are due to metastatic disease. The majority of patients with metastatic disease are treated with systemic agents and/or radiotherapy, which can provide substantial benefit for many patients, prolong survival and improve symptoms. Patients with metastatic cancer are at risk for drug-related toxicity or disease-related complications leading to development of organ failure such as: rhabdomyolysis-associated AKI, liver failure and multi-organ failure often precipitated by endotoxinemia and sepsis. In cases of systemic hyperinflammatory response, mediated by cytokines, to specific treatment with CAR-T cell therapy or in sepsis with or without development of AKI we do not have an effective and specific target molecule oriented therapy. The predicted survival for cancer patients who develop secondary bacterial infection is decreased and it is only treated by the excessive use of antibiotics with the increased antibiotic resistance. Over the past few decades, numerous experimental and clinical studies have investigated the efficacy of extracorporeal blood purification technologies in the treatment of specific indications like in sepsis and septic shock. Thus far, these therapies have failed to demonstrate an improvement in survival when evaluated in randomized trials. In this review article, our goal is to show the possibility of using different hemoadsorbers in specific indications in patients with cancer-related complications, their reported effectiveness in certain indications listed in the text, and the possibility of applying it in cancer patients not only as a last-stand therapy but as well as preventing development of specific organ or multi-organ failure.Ninety percent of all cancer deaths are due to metastatic disease. The majority of patients with metastatic disease are treated with systemic agents and/or radiotherapy, which can provide substantial benefit for many patients, prolong survival and improve symptoms. Patients with metastatic cancer are at risk for drug-related toxicity or disease-related complications leading to development of organ failure such as: rhabdomyolysis-associated AKI, liver failure and multi-organ failure often precipitated by endotoxinemia and sepsis. In cases of systemic hyperinflammatory response, mediated by cytokines, to specific treatment with CAR-T cell therapy or in sepsis with or without development of AKI we do not have an effective and specific target molecule oriented therapy. The predicted survival for cancer patients who develop secondary bacterial infection is decreased and it is only treated by the excessive use of antibiotics with the increased antibiotic resistance. Over the past few decades, numerous experimental and clinical studies have investigated the efficacy of extracorporeal blood purification technologies in the treatment of specific indications like in sepsis and septic shock. Thus far, these therapies have failed to demonstrate an improvement in survival when evaluated in randomized trials. In this review article, our goal is to show the possibility of using different hemoadsorbers in specific indications in patients with cancer-related complications, their reported effectiveness in certain indications listed in the text, and the possibility of applying it in cancer patients not only as a last-stand therapy but as well as preventing development of specific organ or multi-organ failure.